 SAN DIEGO and TORONTO, Aug. 06, 2020 GLOBE NEWSWIRE -- Aptose Biosciences Inc. NASDAQ: APTO, TSX: APS, a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer; Gregory K. Chow, Executive Vice President and Chief Financial Officer; and Joti Marango, M.D., Ph.D, Senior Vice President and Chief Business Officer, will participate in the Canaccord Genuity 40th Annual Growth Conference being held in a virtual format from Tuesday, August 11th to Thursday, August 13th, 2020. Dr. Rice will provide a corporate overview of the Companys recent activities and strategic direction:Aptose Fireside ChatTime: 2:00 p.m. ET Date: Thursday, August 13, 2020A live webcast of the Aptose presentation will be accessible by visiting the following link:Webcast LinkThe webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Companys small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL and non-Hodgkin lymphoma NHL, who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia AML; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia AML or high risk myelodysplastic syndrome MDS. For further information, please contact: Aptose Biosciences Inc. LifeSci Advisors, LLC Greg Chow Dan Ferry, Managing Director Executive Vice President, CFO 617-535-7746 858-926-2730 SMP Communications Susan Pietropaolo 201-923-2049 